Past, Present, and Future Perspectives of Plasminogen Activator Inhibitor 1 (PAI-1)
暂无分享,去创建一个
[1] N. Mutch,et al. Determinants of Endogenous Fibrinolysis in Whole Blood Under High Shear in Patients With Myocardial Infarction , 2022, JACC. Basic to translational science.
[2] J. Knight,et al. The suboptimal fibrinolytic response in COVID‐19 is dictated by high PAI‐1 , 2022, Journal of Thrombosis and Haemostasis.
[3] D. F. Henriques,et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome , 2022, Frontiers in Cellular and Infection Microbiology.
[4] C. Whyte,et al. A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease , 2021, Frontiers in Cardiovascular Medicine.
[5] D. Dwivedi,et al. Biomarkers of coagulation, endothelial function, and fibrinolysis in critically ill patients with COVID‐19: A single‐center prospective longitudinal study , 2021, Journal of Thrombosis and Haemostasis.
[6] G. Lippi,et al. Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study , 2021, Seminars in Thrombosis and Hemostasis.
[7] N. Mackman,et al. Prothrombotic changes in patients with COVID‐19 are associated with disease severity and mortality , 2020, Research and Practice in Thrombosis and Haemostasis.
[8] M. Cecconi,et al. Humanitas COVID-19 Task Force Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy , 2020, Journal of Vascular Surgery: Venous and Lymphatic Disorders.
[9] A. Borczuk,et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City , 2020, Modern Pathology.
[10] J. Laukkanen,et al. Incidence of venous and arterial thromboembolic complications in COVID-19: A systematic review and meta-analysis , 2020, Thrombosis Research.
[11] M. Revel,et al. Pulmonary embolism in patients with COVID-19 pneumonia , 2020, European Respiratory Journal.
[12] Nils Kucher,et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.
[13] M. Ramakers,et al. High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.
[14] D. Gommers,et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.
[15] C. Whyte,et al. Functional plasminogen activator inhibitor 1 is retained on the activated platelet membrane following platelet activation , 2019, Haematologica.
[16] Zhi-juan Li,et al. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: A systematic review and meta-analysis involving 149,908 subjects. , 2018, Gene.
[17] Zheran Liu,et al. PAI-1 Exacerbates White Adipose Tissue Dysfunction and Metabolic Dysregulation in High Fat Diet-Induced Obesity , 2018, Front. Pharmacol..
[18] A. Sauaia,et al. Thrombin stimulates increased plasminogen activator inhibitor-1 release from liver compared to lung endothelium. , 2018, The Journal of surgical research.
[19] M. Saklayen. The Global Epidemic of the Metabolic Syndrome , 2018, Current Hypertension Reports.
[20] Zhenxiang Zhang,et al. Plasminogen activator inhibitor-1: a risk factor for deep vein thrombosis after total hip arthroplasty , 2018, Journal of Orthopaedic Surgery and Research.
[21] K. Ghosh,et al. Investigation of Plasminogen Activator Inhibitor‐1 (PAI‐1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case‐control study , 2017, European journal of haematology.
[22] B. Howard,et al. Relationship between plasma plasminogen activator inhibitor-1 and hypertension in American Indians: findings from the Strong Heart Study , 2017, Journal of hypertension.
[23] D. Rijken,et al. The effects of residual platelets in plasma on plasminogen activator inhibitor-1 and plasminogen activator inhibitor-1-related assays , 2017, PloS one.
[24] A. Metwaly,et al. The Role of Hemostatic Factors in Atherosclerosis in Patients with Chronic Renal Disease , 2015, Electronic physician.
[25] Min Liu,et al. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1* , 2015, The Journal of Biological Chemistry.
[26] H. Kruger,et al. The association of clot lysis time with total obesity is partly independent from the association of PAI-1 with central obesity in African adults. , 2015, Thrombosis research.
[27] K. Lalić,et al. Altered Daytime Fluctuation Pattern of Plasminogen Activator Inhibitor 1 in Type 2 Diabetes Patients with Coronary Artery Disease: A Strong Association with Persistently Elevated Plasma Insulin, Increased Insulin Resistance, and Abdominal Obesity , 2015, International journal of endocrinology.
[28] S. Douma,et al. Increased thrombotic and impaired fibrinolytic response to acute exercise in patients with essential hypertension: The effect of treatment with an angiotensin II receptor blocker , 2014, Journal of Human Hypertension.
[29] Bobbie-Jo M. Webb-Robertson,et al. Mechanisms of Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury , 2013, mBio.
[30] Jeroen J. Bax,et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Blood pressure.
[31] Michael Böhm,et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.
[32] H. Brogren,et al. Platelets Retain High Levels of Active Plasminogen Activator Inhibitor 1 , 2011, PloS one.
[33] D. Tregouet,et al. Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. Results from the D.E.S.I.R. prospective cohort. , 2011, Thrombosis and haemostasis.
[34] P. Eriksson,et al. Gender-specific association of the plasminogen activator inhibitor-1 4G/5G polymorphism with central arterial blood pressure. , 2011, American journal of hypertension.
[35] R. Saif-Ali,et al. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects , 2011, Cardiovascular diabetology.
[36] A. Fernandes,et al. Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke , 2011, Molecular Biology Reports.
[37] B. Furie,et al. Structural Basis for Recognition of Urokinase-type Plasminogen Activator by Plasminogen Activator Inhibitor-1* , 2011, The Journal of Biological Chemistry.
[38] J. Higaki,et al. [Chronic renal disease]. , 2011, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.
[39] O. Tiryaki,et al. Plasma Plasminogen Activator Inhibitor 1 (PAI-1) and p-Selectin Levels in Urgent Hypertension: Effect of Single Dose Captopril and Nifedipin on Fibrinolytic Activity , 2010, Clinical and experimental hypertension.
[40] F. Rosendaal,et al. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. , 2010, Blood.
[41] A. Biswas,et al. Plasminogen Activator Inhibitor-1 (PAI-1) Gene 4G/5G Promoter Polymorphism is Seen in Higher Frequency in the Indian Patients With Deep Vein Thrombosis , 2010, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[42] S. Grundy,et al. The metabolic syndrome. , 2008, Endocrine reviews.
[43] P. Marik,et al. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. , 2009, Chest.
[44] P. Pelosi,et al. Lung parenchyma remodeling in acute respiratory distress syndrome. , 2009, Minerva anestesiologica.
[45] D. Levy,et al. Multimarker Approach to Evaluate Correlates of Vascular Stiffness: The Framingham Heart Study , 2009, Circulation.
[46] P. Andreasen,et al. Biochemical properties of plasminogen activator inhibitor-1. , 2009, Frontiers in bioscience.
[47] E. Kruithof. Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins , 2008, Thrombosis and Haemostasis.
[48] David R. Croucher,et al. Revisiting the biological roles of PAI2 (SERPINB2) in cancer , 2008, Nature Reviews Cancer.
[49] H. Teede,et al. Relationship of waist and hip circumference with coagulation and fibrinolysis in postmenopausal women. , 2007, Clinical science.
[50] D. Levy,et al. Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study , 2007, Circulation.
[51] N. Booth,et al. TAFIa, PAI‐1 and α2‐antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots , 2007, Journal of thrombosis and haemostasis : JTH.
[52] Z. Israili,et al. Fibrinolytic System in Normotensive Subjects and Hypertensive Patients , 2007 .
[53] D. Glidden,et al. Increased Plasminogen Activator Inhibitor-1 Concentrations in Bronchoalveolar Lavage Fluids Are Associated with Increased Mortality in a Cohort of Patients with Pseudomonas aeruginosa , 2007, Anesthesiology.
[54] P. Parsons,et al. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome* , 2006, Critical care medicine.
[55] Z. Li,et al. Expression of elevated levels of pro‐inflammatory cytokines in SARS‐CoV‐infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS† , 2006, The Journal of pathology.
[56] M. Alessi,et al. PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[57] D. L. Crandall,et al. Modulation of Adipose Tissue Development by Pharmacological Inhibition of PAI-1 , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[58] P. Krespi,et al. White coat hypertension and haemostatic/fibrinolytic balance disorders. , 2006, European cytokine network.
[59] M. Simons,et al. Plasminogen and plasmin activity in patients with coronary artery disease , 2006, Journal of thrombosis and haemostasis : JTH.
[60] M. Schultz,et al. Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inflammation , 2006, Intensive Care Medicine.
[61] J. Ruige,et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome , 2006, International Journal of Obesity.
[62] D. Levy,et al. Comprehensive Survey of Common Genetic Variation at the Plasminogen Activator Inhibitor-1 Locus and Relations to Circulating Plasminogen Activator Inhibitor-1 Levels , 2005, Circulation.
[63] N. Nagai,et al. Effects of plasminogen activator inhibitor‐1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice , 2005, Journal of thrombosis and haemostasis : JTH.
[64] H. Im,et al. The length of the reactive center loop modulates the latency transition of plasminogen activator inhibitor‐1 , 2005, Protein science : a publication of the Protein Society.
[65] A. E. El Solh,et al. Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis , 2005, Intensive Care Medicine.
[66] H. Brogren,et al. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. , 2004, Blood.
[67] A. Gils,et al. Plasminogen activator inhibitor-1. , 2004, Current medicinal chemistry.
[68] E. Coban,et al. The plasma levels of plasminogen activator inhibitor‐1 in subjects with white coat hypertension , 2004, International journal of clinical practice.
[69] H. Hauner,et al. Effect of the angiotensin II receptor blocker candesartan on fibrinolysis in patients with mild hypertension , 2004, Diabetes, obesity & metabolism.
[70] P. Simioni,et al. The PAI-I gene 4G/5G Polymorphism and Deep Vein Thrombosis in Patients with Inherited Thrombophilia , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[71] E. Vicaut,et al. Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality , 2003, Circulation.
[72] S. Yusuf,et al. Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease , 2003, Circulation.
[73] M. Matthay,et al. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. , 2003, American journal of physiology. Lung cellular and molecular physiology.
[74] S. Haffner,et al. Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study , 2003, Circulation.
[75] D. Grobbee,et al. The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. , 2003, Blood.
[76] J. Geleijnse,et al. Diurnal Variation in PAI-1 Activity Predominantly Confined to the 4G-allele of the PAI-1 Gene , 2002, Thrombosis and Haemostasis.
[77] Peter Hufnagl,et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. , 2002, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.
[78] S. Haffner,et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.
[79] D. Bastelica,et al. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss , 2001, Diabetologia.
[80] F. España,et al. Plasma PAI-1 Levels in Obese Children – Effect of Weight Loss and Influence of PAI-1 Promoter 4G/5G Genotype , 2001, Thrombosis and Haemostasis.
[81] R. Read,et al. Structure of a serpin–protease complex shows inhibition by deformation , 2000, Nature.
[82] B. Fagerberg,et al. Insulin Sensitivity and Hemostatic Factors in Clinically Healthy 58-year-old Men , 2000, Thrombosis and Haemostasis.
[83] P. Grant,et al. Plasminogen-activator inhibitor type 1 and coronary artery disease. , 2000, The New England journal of medicine.
[84] D. Levy,et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. , 2000, Circulation.
[85] D. Singer,et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. , 2000, JAMA.
[86] E. Bruckert,et al. Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 gene during very low calorie diet in obese subjects , 2000, International Journal of Obesity.
[87] J. Bastard,et al. Plasma plasminogen activator inhibitor 1, insulin resistance and android obesity. , 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[88] B. Binder,et al. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[89] P. Morange,et al. PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[90] H. Saito,et al. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. , 1998, International journal of hematology.
[91] D. Vaughan,et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. , 1998, Hypertension.
[92] L. Weinehall,et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. , 1998, Circulation.
[93] S. Moestrup,et al. Plasminogen Activator Inhibitor 1 Contains a Cryptic High Affinity Receptor Binding Site that Is Exposed upon Complex Formation with Tissue-type Plasminogen Activator , , 1998, Thrombosis and Haemostasis.
[94] A. Hamsten,et al. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals , 1998, Diabetologia.
[95] D. Loskutoff,et al. The adipocyte and hemostatic balance in obesity: studies of PAI-1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[96] B. Wiman,et al. Plasminogen activator inhibitor-1 (PAI-1) content in platelets from healthy individuals genotyped for the 4G/5G polymorphism in the PAI-1 gene. , 1997, Scandinavian journal of clinical and laboratory investigation.
[97] A. Shapiro,et al. Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. , 1997, Blood.
[98] P. Morange,et al. Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease , 1997, Diabetes.
[99] P. Nilsson,et al. Increased levels of tissue plasminogen activator antigen in essential hypertension. A population‐based study in Sweden , 1997, Journal of hypertension.
[100] C. Fearns,et al. Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. , 1997, The American journal of pathology.
[101] S. Thompson,et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.
[102] J. Abrahams,et al. Inhibitory conformation of the reactive loop of α1-antitrypsin , 1996, Nature Structural Biology.
[103] S. Yamashita,et al. Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty , 1996, Nature Medicine.
[104] D. Lawrence,et al. Plasminogen Activator Inhibitor-1 and Vitronectin Promote the Cellular Clearance of Thrombin by Low Density Lipoprotein Receptor-related Proteins 1 and 2 (*) , 1996, The Journal of Biological Chemistry.
[105] B. Bennett,et al. Proteins of the Fibrinolytic System in Human Thrombi , 1996, Thrombosis and Haemostasis.
[106] E. Barnathan,et al. Plasminogen activator system in human coronary atherosclerosis. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[107] H. Wright,et al. Structural basis for serpin inhibitor activity , 1995, Proteins.
[108] B. Wiman. Plasminogen Activator Inhibitor 1 (PAI-1) in Plasma: Its Role in Thrombotic Disease , 1995, Thrombosis and Haemostasis.
[109] D. Vaughan,et al. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. , 1995, The Journal of clinical investigation.
[110] I. Juhan-vague,et al. Detection of Plasminogen Activator Inhibitor-1 (PAI-1) mRNA in Human Megakaryocytes by In Situ Hybridization , 1994, Thrombosis and Haemostasis.
[111] M. Alessi,et al. Plasminogen Activator Inhibitor-1 Expression in Human Liver and Healthy or Atherosclerotic Vessel Walls , 1994, Thrombosis and Haemostasis.
[112] S. Thompson,et al. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[113] G. Bergonzelli,et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[114] B. Konkle,et al. Plasminogen activator inhibitor-1 mRNA is expressed in platelets and megakaryocytes and the megakaryoblastic cell line CHRF-288. , 1993, Arteriosclerosis and Thrombosis A Journal of Vascular Biology.
[115] T. Nilsson,et al. Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals. , 1992, Metabolism: clinical and experimental.
[116] D. Loskutoff,et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[117] D. Loskutoff,et al. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. , 1991, The Journal of clinical investigation.
[118] H. Ehrlich,et al. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance. , 1991, Blood.
[119] D. Loskutoff,et al. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. , 1991, The Journal of biological chemistry.
[120] B. Bennett,et al. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. , 1991, Journal of clinical pathology.
[121] P. Quax,et al. Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. , 1990, The Journal of biological chemistry.
[122] D. Loskutoff,et al. The Fibrinolytic System of the Vessel Wall and Its Role in the Control of Thrombosis , 1990, Annals of the New York Academy of Sciences.
[123] F. Lemaire,et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. , 1990, The New England journal of medicine.
[124] T. Martin,et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. , 1989, The Journal of clinical investigation.
[125] J. Mimuro,et al. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. , 1989, The Journal of biological chemistry.
[126] B. Sobel,et al. Regulation of the expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. , 1988, The Journal of biological chemistry.
[127] B. Bennett,et al. Plasminogen activator inhibitor (PAI‐1) in plasma and platelets , 1988, British journal of haematology.
[128] K. Preissner,et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). , 1988, The Journal of biological chemistry.
[129] A. Maseri,et al. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. , 1988, The American journal of cardiology.
[130] B. Alving,et al. Plasminogen activator and plasminogen activator inhibitor activities in a reference population. , 1988, American journal of clinical pathology.
[131] M. Blombäck,et al. PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.
[132] C. Kluft,et al. Plasminogen activator inhibitors. , 1987, Blood.
[133] R. Lebo,et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. , 1986, The Journal of clinical investigation.
[134] J. Millán,et al. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[135] M. Alessi,et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. , 1986, Metabolism: clinical and experimental.
[136] M. Blombäck,et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. , 1985, The New England journal of medicine.
[137] D. Loskutoff,et al. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. , 1985, The Journal of biological chemistry.
[138] B. Bennett,et al. Platelet release protein which inhibits plasminogen activators. , 1985, Journal of clinical pathology.
[139] D. Ph.DCollenM.. Report of the Meeting of the Subcommittee on Fibrinolysis, San Diego, CA, USA, July 13, 1985 , 1985 .
[140] D. Lawrence,et al. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. , 1984, The Journal of biological chemistry.
[141] D. Loskutoff,et al. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. , 1984, The Journal of clinical investigation.
[142] E. Kruithof,et al. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.
[143] B. Wiman,et al. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. , 1983, Thrombosis research.
[144] D. Lawrence,et al. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[145] I. Clemmensen,et al. The primary inhibitor of plasmin in human plasma. , 1976, The Biochemical journal.
[146] N. Aoki,et al. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. , 1976, The Journal of biological chemistry.
[147] D. Collen. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. , 1976, European journal of biochemistry.
[148] T. Astrup,et al. SELECTIVE INHIBITION IN HUMAN PREGNANCY BLOOD OF UROKINASE INDUCED FIBRINOLYSIS. , 1963, Scandinavian journal of clinical and laboratory investigation.
[149] T. Rephann,et al. Association , 1973, ACM SIGSPATIAL International Workshop on Advances in Geographic Information Systems.